Skip to content

Transverse vs Longitudinal Mucosal Incision During POEM

Transverse Versus Longitudinal Mucosal Incision in Peroral Endoscopic Myotomy: A Multicenter Randomized Clinical Trial

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07425977
Enrollment
140
Registered
2026-02-23
Start date
2026-02-22
Completion date
2026-08-02
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Achalasia, Spastic Esophageal Motility Disorders

Brief summary

Peroral endoscopic myotomy (POEM) is a minimally invasive endoscopic procedure used to treat achalasia and other spastic esophageal motility disorders. A key step in POEM is creating a small opening in the esophageal lining (mucosal incision) to enter the submucosal tunnel. This study evaluates whether making that entry incision \*\*transverse\*\* (across the esophagus) versus \*\*longitudinal\*\* (along the esophagus) improves procedural efficiency without reducing safety. This is a \*\*multicenter, randomized (1:1), parallel-group clinical trial\*\* conducted in three therapeutic endoscopy units in Colombia (Hospital Universitario del Valle and Clínica Versalles in Cali, and Clínica del Occidente in Bogotá). Adults (≥18 years) with an indication for POEM, ASA I-III, and ability to provide informed consent will be eligible; key exclusions include prior myotomy/major esophageal surgery, uncorrectable coagulopathy, pregnancy, active systemic infection, anesthesia contraindication, or anticipated technical inability to perform POEM. All procedures are standardized: POEM under \*\*general anesthesia with orotracheal intubation\*\*, \*\*CO₂ insufflation\*\*, validated endoscopic knives and preset electrosurgical modes; hemostasis with \*\*Coagrasper® only if needed\*\*; and closure using standard \*\*through-the-scope (TTS) clips\*\*. Participants are randomly assigned to a \*\*15 mm transverse mucosal incision\*\* (perpendicular to the esophageal axis) or a \*\*15 mm longitudinal mucosal incision\*\*. Full-procedure video is recorded for quality control and to allow objective timing, with blinded assessment of the primary outcome. The \*\*primary outcome\*\* is the time (seconds) from the first mucosal cut to successful entry of the endoscope cap into the submucosal tunnel (advancing at least 1 cm). \*\*Secondary outcomes\*\* include need for hemostasis with Coagrasper®, number of clips required for complete closure, and early complications (including perforation and gas-related events such as capnoperitoneum requiring decompression and emphysema), monitored through \*\*30 days\*\*. Participants complete a screening/preoperative visit (up to 30 days before), undergo the POEM procedure, have early in-hospital/discharge assessment (days 1-2), and receive safety follow-up contacts at approximately 1 week and day 30. Risks are those expected from standard POEM and peri-anesthesia care (e.g., bleeding, perforation, infection, and gas-related complications), and participants may not directly benefit clinically. However, the transverse incision may shorten access and closure time and reduce resource use without increasing short-term complications. The study will be conducted with written informed consent, confidentiality protections (pseudonymization and secure storage), and reporting of results in aggregate form.

Interventions

PROCEDURETransverse Mucosal Incision During POEM

POEM performed with a 15 mm transverse mucosal incision (perpendicular to the esophageal axis) for entry into the submucosal tunnel, under a standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).

PROCEDURELongitudinal Mucosal Incision During POEM

POEM performed with a 15 mm longitudinal mucosal incision (parallel to the esophageal axis) for entry into the submucosal tunnel, under the same standardized POEM protocol (general anesthesia with orotracheal intubation, CO₂ insufflation, validated endoscopic knives/electrosurgical settings, hemostasis with Coagrasper® only if needed, and closure with TTS clips; full-procedure video recorded).

Sponsors

Universidad Nacional de Colombia
Lead SponsorOTHER
Hospital San Rafael de Facatativá
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Operator blinding is not feasible due to the nature of the techniques. Participants will remain masked. The primary outcome time will be extracted objectively using automatic timestamps/logs and assessed by masked evaluators; statistical analyses will be performed using masked group labels (A/B). Individual unmasking will be limited to clinical circumstances requiring it.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Diagnosis of achalasia or other spastic esophageal motility disorders with an indication for POEM * ASA physical status I-III * Ability to provide informed consent

Exclusion criteria

* Prior myotomy or major esophageal surgery * Uncorrectable coagulopathy * Pregnancy * Active systemic infection * Contraindication to anesthesia * Any situation predicting technical inability to perform POEM

Design outcomes

Primary

MeasureTime frameDescription
Time to Effective Submucosal Tunnel Entry (Seconds)During the POEM procedure (Day 0; intraoperative)Time (in seconds) from the first mucosal cut to effective entry of the endoscope cap into the submucosal tunnel, defined as allowing advancement of at least 1 cm.

Secondary

MeasureTime frameDescription
Bleeding Requiring Hemostasis With Coagrasper®During the POEM procedure (Day 0; intraoperative)Proportion of procedures with bleeding that requires hemostasis using Coagrasper® (Yes/No).
Procedure-Related Complications (Up to 30 Days)Up to 30 days after the procedure (contacts at ~1 week and Day 30; plus early assessment Days 1-2).Any complication related to the procedure, monitored through 30 days.

Countries

Colombia

Contacts

CONTACTJuan P Alzate, MD, MsC
jpalzategr@unal.edu.co+573102587912

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026